Pathways > Drug resistance of FLT3 mutants
Page last updated: 2024-10-06
Drug resistance of FLT3 mutants
Proteins (1)
| Protein | Synonyms | Taxonomy |
|---|
| Receptor-type tyrosine-protein kinase FLT3 | EC 2.7.10.1; FL cytokine receptor; Fetal liver kinase-2; FLK-2; Fms-like tyrosine kinase 3; FLT-3; Stem cell tyrosine kinase 1; STK-1 | Homo sapiens (human) |
Compounds (4)
| Compound | Description |
|---|
| sorafenib | A niacinamide and phenylurea derivative that inhibits multiple intracellular and cell surface kinases thought to be involved in ANGIOGENESIS, including RAF KINASES and VEGF RECEPTORS. It is used in the treatment of advanced RENAL CELL CARCINOMA and HEPATOCELLULAR CARCINOMA, and for treatment of THYROID CARCINOMA refractory to radioactive iodine therapy. |
| pexidartinib | inhibits both CSF1R and c-kit receptor tyrosine kinase; structure in first source |
| midostaurin | |
| kw 2449 | has both multikinase inhibitory activity and antineoplastic activity; structure in first source |